Community Resiliency Collective Efficacy Intervention
Launched by UNIVERSITY OF PITTSBURGH · Mar 12, 2023
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Community Resiliency Collective Efficacy Intervention, is looking at a special program designed to help communities become stronger and more resilient in order to reduce violence. The study will focus on neighborhoods that are affected by different types of violence, including community violence and domestic violence, and will involve both youth aged 13 and older and adults aged 18 and older. By participating, individuals will contribute to understanding how community support and connections can make a difference in reducing violence in their area.
To be eligible for this trial, you must be at least 13 years old and live in one of the neighborhoods selected for the study. If you’re chosen to participate, you can expect to take part in activities that aim to build social connections and promote resilience in your community. This trial is currently recruiting participants, and it welcomes individuals of all genders. Your involvement could help create a safer environment for everyone in your community.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • youth age 13 years old and up (all genders)
- • adults 18 years and older (all genders)
- • reside in neighborhoods selected to participate in the study
- Exclusion Criteria:
- • individuals younger than 13 years old
- • individuals residing outside of participating neighborhoods
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Elizabeth Miller, MD, PhD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials